INTRODUCTION: MicroRNAs (miRNAs) are short non-coding RNAs that have the ability to regulate gene expression at the post-transcriptional level. MiRNAs are deregulated in many cancer types, and several miRNAs have been suggested as novel diagnostic and prognostic biomarkers in diffuse large B-cell lymphoma (DLBCL). The objective of this study was to systematically collect and evaluate current knowledge of miRNAs functioning as diagnostic and prognostic biomarkers within DLBCL. METHODS: This review was conducted according to the Preferred Reporting for Systematic Reviews and Meta-analyses guidelines. A systematic search of literature in PubMed and Embase was made and supplemented by screening of reference lists. Only original peer-reviewed studies written in English were included and screened based on miRNA expression, molecular subtypes of DLBCL and patient outcome. RESULTS: Out of 277 candidate records, a total of 20 studies qualified for inclusion in this review. In all, 11 studies reported a total of 48 miRNAs with expression patterns associated with specific molecular DLBCL subtypes, and 14 studies reported a total of 30 miRNAs associated with patient outcome. However, only few miRNAs showed significant results in more than one study. CONCLUSION: MiRNAs qualify as potential diagnostic and prognostic biomarkers in DLBCL. However, more clinical validation including prospective and cross-centre studies are required before specific miRNAs can be integrated into the daily practice as biomarkers in DLBCL, which would contribute to an era of more personalised medicine.
INTRODUCTION: MicroRNAs (miRNAs) are short non-coding RNAs that have the ability to regulate gene expression at the post-transcriptional level. MiRNAs are deregulated in many cancer types, and several miRNAs have been suggested as novel diagnostic and prognostic biomarkers in diffuse large B-cell lymphoma (DLBCL). The objective of this study was to systematically collect and evaluate current knowledge of miRNAs functioning as diagnostic and prognostic biomarkers within DLBCL. METHODS: This review was conducted according to the Preferred Reporting for Systematic Reviews and Meta-analyses guidelines. A systematic search of literature in PubMed and Embase was made and supplemented by screening of reference lists. Only original peer-reviewed studies written in English were included and screened based on miRNA expression, molecular subtypes of DLBCL and patient outcome. RESULTS: Out of 277 candidate records, a total of 20 studies qualified for inclusion in this review. In all, 11 studies reported a total of 48 miRNAs with expression patterns associated with specific molecular DLBCL subtypes, and 14 studies reported a total of 30 miRNAs associated with patient outcome. However, only few miRNAs showed significant results in more than one study. CONCLUSION: MiRNAs qualify as potential diagnostic and prognostic biomarkers in DLBCL. However, more clinical validation including prospective and cross-centre studies are required before specific miRNAs can be integrated into the daily practice as biomarkers in DLBCL, which would contribute to an era of more personalised medicine.
Authors: Afshin Beheshti; Charles Vanderburg; J Tyson McDonald; Charusheila Ramkumar; Tatenda Kadungure; Hong Zhang; Ronald B Gartenhaus; Andrew M Evens Journal: PLoS One Date: 2017-01-20 Impact factor: 3.240
Authors: Afshin Beheshti; Kristen Stevenson; Charles Vanderburg; Dashnamoorthy Ravi; J Tyson McDonald; Amanda L Christie; Kay Shigemori; Hallie Jester; David M Weinstock; Andrew M Evens Journal: Sci Rep Date: 2019-11-20 Impact factor: 4.379
Authors: Benyamin Ranjbar; Louise Bechmann Krogh; Maria Bach Laursen; Maria Nascimento Primo; Sara Correia Marques; Karen Dybkær; Jacob Giehm Mikkelsen Journal: PLoS One Date: 2016-04-05 Impact factor: 3.240
Authors: Hanne Due; Pernille Svendsen; Julie Støve Bødker; Alexander Schmitz; Martin Bøgsted; Hans Erik Johnsen; Tarec Christoffer El-Galaly; Anne Stidsholt Roug; Karen Dybkær Journal: Biomed Res Int Date: 2016-05-16 Impact factor: 3.411